FDA Approves WELIREG — Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC received FDA approval for its belzutifan tablets (WELIREG) to treat about half of individuals with von Hippel-Lindau disease, launching a new market opportunity in rare genetic disorders. This approval comes just months after the company voluntarily paused U.S. sales of Mirvetuximab Soravtansine due to future manufacturing concerns, signaling the company's aggressive focus on returning top-line growth to its oncology portfolio.